Insider Selling: Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells $642,583.00 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 37,799 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total transaction of $642,583.00. Following the sale, the insider owned 9,174,453 shares of the company’s stock, valued at $155,965,701. This trade represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

• On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.13, for a total value of $428,712.51.
• On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $16.93 on Friday. The firm has a market cap of $872.74 million, a P/E ratio of 7.70 and a beta of 0.17. Theravance Biopharma, Inc. has a 1-year low of $10.82 and a 1-year high of $21.03. The business’s 50 day moving average is $16.58 and its 200-day moving average is $17.27.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The firm had revenue of $17.70 million for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. Analysts forecast that Theravance Biopharma, Inc. will post 1.54 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings lowered shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. JonesTrading cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. TD Cowen boosted their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a report on Monday, March 23rd. Finally, BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday. One equities research analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $21.40.

Hedge Funds Weigh In On Theravance Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. JPMorgan Chase & Co. grew its stake in Theravance Biopharma by 78.3% during the third quarter. JPMorgan Chase & Co. now owns 213,104 shares of the biopharmaceutical company’s stock worth $3,111,000 after buying an additional 93,591 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of Theravance Biopharma in the 3rd quarter valued at approximately $1,118,000. UBS Group AG lifted its holdings in shares of Theravance Biopharma by 10.9% during the 4th quarter. UBS Group AG now owns 570,425 shares of the biopharmaceutical company’s stock worth $10,673,000 after acquiring an additional 56,255 shares during the period. Ellsworth Advisors LLC bought a new stake in shares of Theravance Biopharma during the 4th quarter worth approximately $670,000. Finally, Pacer Advisors Inc. acquired a new stake in shares of Theravance Biopharma during the 4th quarter worth approximately $6,342,000. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.